📈 Jumpstart Signal Watchlist — August 18, 2026

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $13.89 is 5% below 3yr high $14.66 · ⏳ SMA200 $9.33 (current price $13.89 is above) · 💰 Market Cap $1.3B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (8.5%)
- 🔔 Strong above EMA50 (14.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ MeiraGTx Reports Second Quarter 2026 Financial and Operational Results — Yahoo Finance / Globe Newswire.
🤖 MeiraGTx reported strong second-quarter 2026 results, including positive three-year data for AAV2-hAQP1 and FDA Breakthrough Therapy Designation. The update also highlighted completion of the bota-vec acquisition, which adds a nearer-term pipeline opportunity.
✅ MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada — MarketBeat.
🤖 RBC raised its price target on MeiraGTx to $27 from $26 and maintained an outperform rating. That kind of analyst action usually supports sentiment by signaling improved expectations for the stock.
⚪️ MeiraGTx (NASDAQ:MGTX) CFO Richard Giroux Sells 56,000 Shares — MarketBeat.
🤖 This is an insider sale, which can attract attention but does not by itself change the company’s operating outlook. The same coverage also references prior analyst support and company actions, so the overall market impact is limited and mixed.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: The Manitowoc Company is a global manufacturer of engineered lifting solutions, mainly cranes and related equipment. Its products include mobile hydraulic cranes, tower cranes, crawler cranes, boom trucks, and associated aftermarket services and support.
- 🎯 Current $19.30 is 8% below 3yr high $20.87 · ⏳ SMA200 $13.06 (current price $19.30 is above) · 💰 Market Cap $696M
- MTW shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 875% (>20%); Low LT D/E 0.66 (<1.0); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (13.4%)
- 🔔 Strong above EMA50 (27.7%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ U.S. Government Affirms Manitowoc's Anti-Dumping Claim — Business Wire / Yahoo Finance.
🤖 The U.S. government’s affirmative anti-dumping decision could support Manitowoc’s competitive position in lattice-boom crawler cranes. Management said the ruling helps restore fair competition and supports U.S. manufacturing operations.
✅ Manitowoc Q2 2026 slides: orders surge 56%, guidance raised on AI gains — Investing.com.
🤖 The article highlights a strong quarter with 56% order growth, backlog above $1 billion, and higher full-year guidance. Those results suggest improving fundamentals and a favorable reaction from investors.
⚪️ Renaissance Technologies LLC Cuts Holdings in The Manitowoc Company, Inc. $MTW — MarketBeat.
🤖 This filing notes a large investor reduced its MTW position, but the article also references the company’s strong Q2 results and raised 2026 guidance. The ownership change is not clearly a strong standalone positive or negative catalyst for the stock.
⚪️ The Manitowoc Company Schedules Second-Quarter 2026 Earnings Announcement and Conference Call — Business Wire.
🤖 This is a bare earnings-date announcement with no results, guidance, or analyst opinion. It is not meaningful stock news on its own and is excluded from sentiment impact.
🍭 Bonus (B): 0/10 — Construction Machinery

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.30 is 6% below 3yr high $15.26 · ⏳ SMA200 $9.21 (current price $14.30 is above) · 💰 Market Cap $967M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.9%)
- 🔔 Strong above EMA50 (17.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says — MarketBeat.
🤖 Canaccord Genuity raised its price target on Bioventus to $19 from $15 and kept a buy rating. The note also reflects a broadly favorable analyst backdrop after the company’s latest quarter matched expectations and management provided FY2026 guidance.
✅ Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald — MarketBeat.
🤖 Cantor Fitzgerald reiterated an overweight rating and a $15 price target for Bioventus. The article also highlights that the company matched quarterly EPS expectations and issued FY2026 guidance, which supports a constructive view.
⚪️ Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings ... — MarketBeat.
🤖 This report focused on Bioventus issuing FY2026 EPS guidance of $0.75 to $0.79 and revenue guidance of $600 million to $610 million. The guidance was broadly in line with estimates, making the reaction mixed rather than strongly bullish or bearish.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $35.05 is 1% below 3yr high $35.53 · ⏳ SMA200 $24.16 (current price $35.05 is above) · 💰 Market Cap $4.5B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.1%)
- 🔔 Strong above EMA50 (13.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High — MarketBeat.
🤖 Shares hit a new 52-week high, reflecting strong recent momentum in the stock. The article also points to favorable analyst coverage and the company’s prior earnings beat, both supportive for sentiment.
✅ Concentra Group Holdings Parent (NYSE:CON) Reaches New 12-Month High After Earnings Beat — MarketBeat.
🤖 The company reported quarterly EPS and revenue above expectations, and management raised its 2026 outlook. That combination of a beat and improved guidance is constructive for the stock.
⚪️ Concentra Group Holdings Parent, Inc. Plans Quarterly Dividend of $0.06 — MarketBeat.
🤖 The article is mainly a dividend announcement, which is a routine capital-return update rather than a major growth catalyst. It does not materially change the stock’s near-term earnings outlook.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: Consensus Cloud Solutions, Inc. (CCSI) is a leading provider of digital cloud faxing services and interoperability solutions, primarily through a SaaS platform that enables secure faxing via email, web portals, APIs, and mobile apps.
- 🎯 Current $38.09 is 3% below 3yr high $39.10 · ⏳ SMA200 $28.38 (current price $38.09 is above) · 💰 Market Cap $699M
- CCSI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 34% (>20%); ROE 228% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.23 (<1.5).
⏰ Entry (E): 3/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Consensus Cloud Solutions (NASDAQ:CCSI) Trading Up 4.7% - Here's What Happened — MarketBeat.
🤖 The article says CCSI rose 4.7% on the day and links the move to the company’s recently issued Q3 and FY 2026 guidance. It is favorable because the guidance and stock reaction suggest investors viewed the update positively.
✅ Consensus Cloud Solutions (NASDAQ:CCSI) Trading Up 8.5% After Analyst Upgrade — MarketBeat.
🤖 This article reports that analysts remained broadly constructive and that the stock moved higher after an upgrade-related report. Rising price targets and a buy rating are generally supportive for the stock.
❌ Consensus Cloud Solutions (NASDAQ:CCSI) Stock Price Down 6.2% Following Insider Selling — MarketBeat.
🤖 The piece focuses on a share-price decline tied to insider selling, which can weigh on investor sentiment. It also notes analyst support, but the main near-term trading signal is negative.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Remitly Global, Inc. is a digital financial services provider that offers cross-border remittance and international money transfer services primarily for immigrants and their families through a mobile app and website .
- 🎯 Current $25.44 is 8% below 3yr high $27.59 · ⏳ SMA200 $17.90 (current price $25.44 is above) · 💰 Market Cap $5.4B
- RELY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 3000% (>20%); Revenue growth 20% (>15%); ROE 27% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Remitly Reports Record Second Quarter Results and Raises Full Year 2026 Outlook — GlobeNewswire.
🤖 Remitly reported record Q2 results, with revenue up 20% year over year and adjusted EBITDA up sharply, while also raising its full-year 2026 outlook. That combination of strong execution and improved guidance is positive for RELY.
✅ Remitly Global, Inc. (RELY) Q2 Earnings and Revenues Surpass Estimates — Yahoo Finance / Zacks.
🤖 The company beat analyst estimates on both earnings and revenue for Q2 2026, which typically supports the stock. The article also highlights an earnings surprise and strong top-line growth, both favorable for RELY.
✅ Remitly Is Up 7.2% After Strong Q2 Beat And Launch Of Global Multi-Currency Card — Yahoo Finance / Simply Wall St.
🤖 This article links the post-earnings share strength to both a strong Q2 beat and the launch of a new Global Card product. The product expansion adds a new growth catalyst beyond core remittances, which is positive for RELY.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Avnet, Inc. is a global distributor of electronic components and a technology solutions provider that supports engineers, entrepreneurs, and startups in taking tech projects from idea and design to prototype and mass production.
- 🎯 Current $93.40 is 5% below 3yr high $98.63 · ⏳ SMA200 $68.46 (current price $93.40 is above) · 💰 Market Cap $7.7B
- AVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1578% (>20%); Revenue growth 48% (>15%); Low LT D/E 0.39 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Capital Financial Group Inc. Co. ADV Makes New $1.16 ... — MarketBeat.
🤖 The item highlights multiple analyst upgrades and higher price targets for Avnet, alongside a generally bullish consensus. That kind of analyst support is typically positive for the stock.
✅ Avnet, Inc. Given Consensus Recommendation of Moderate Buy by Brokerages — MarketBeat.
🤖 This article says covering analysts collectively rate Avnet as a Moderate Buy and cites a strong earnings beat and dividend announcement. The combination of stronger fundamentals and supportive analyst sentiment is positive for AVT.
⚪️ Avnet, Inc. $AVT Shares Bought by Hsbc Holdings PLC — MarketBeat.
🤖 This is a routine institutional ownership filing, showing HSBC increased its Avnet stake in the first quarter. It does not contain new operational developments, so it is neutral for the stock.
🍭 Bonus (B): 0/10 — Electronic Parts - Wholesale

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $46.18 is 4% below 3yr high $47.85 · ⏳ SMA200 $22.78 (current price $46.18 is above) · 💰 Market Cap $2.4B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (7.9%)
- 🔔 Strong above EMA50 (27.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ CareDx Announces Second Quarter 2026 Financial Results — Business Wire.
🤖 CareDx reported Q2 2026 revenue growth of 52% to $132 million and raised full-year 2026 revenue and adjusted EBITDA guidance. The strong beat on results and higher outlook are positive for CDNA.
✅ Zacks Research Upgrades CareDx (NASDAQ:CDNA) to Strong-Buy — MarketBeat.
🤖 Zacks Research raised CareDx to Strong-Buy, adding to a wave of favorable analyst commentary after the company’s strong quarterly results. Analyst upgrades tend to support the stock by improving sentiment and valuation expectations.
⚪️ CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of Hold from Analysts — MarketBeat.
🤖 This article mainly summarizes the analyst consensus as Hold even though it notes CareDx’s strong quarterly results and several upgraded price targets. The mixed analyst backdrop makes the impact on the stock more balanced than clearly positive.
🍭 Bonus (B): 0/10 — Medical Laboratories